Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: a multicentre independent study supported by the Italian Drug Agency.

doi:10.1016/j.dld.2014.05.014

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: a multicentre independent study supported by the Italian Drug Agency.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver - 1 Sept 2014

Rosina Floriano, Tosti Maria Elena, Borghesio Elisabetta, Masocco Maria, Mele Alfonso, Coppola Carmine, Milella Michele, Borgia Guglielmo, Andreone Pietro, Koch Maurizio, Zignego Anna Linda, Romano Mario, Carrara Maurizio, Almasio Piero Luigi, Azzola Emilio, Nardone Gerardo, Benedetti Antonio, Carosi Giampiero, Mazzotta Francesco, Sagnelli Evangelista, Rizzetto Mario

Abstract excerpt

BACKGROUND: Data on the efficacy of Peg-interferon/ribavirin therapy for chronic hepatitis C are mostly derived from treatment of selected patients enrolled in clinical trials. This study aimed to assess the effectiveness of Peg-interferon/ribavirin therapy in "real world" chronic hepatitis C patients in Italy. METHODS: Independent observational multicentre study including consecutive patients receiving...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Carriers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Italy

Share to Polyethylene Glycols

Share to Registries

Share to Ribavirin

Source

Open in PubMed

Identifiers

PMID: 24986781
DOI: 10.1016/j.dld.2014.05.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: a multicentre independent study supported by the Italian Drug Agency.PMID 24986781Read ↗

Real-world outcomes in patients with chronic hepatitis C: primary results of the PROBE study.Semantic proximity Read ↗

Chronic hepatitis C treated with peginterferon alfa plus ribavirin in clinical practice.Semantic proximity Read ↗

Treatment of hepatitis C with peginterferon and ribavirin in a public health program.Semantic proximity Read ↗

Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.Semantic proximity Read ↗

Antiviral treatment of chronic hepatitis C in clinical routine.Semantic proximity Read ↗

Treatment Outcomes and Predictors of Response in Treatment-Naive HCV Patients Treated with Peginterferon Alfa/Ribavirin in Real-World Italian Clinics: Sub-Analysis from the PROPHESYS Cohort.Semantic proximity Read ↗

Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.Semantic proximity Read ↗

Peginterferon and ribavirin treatment for hepatitis C virus infection.Semantic proximity Read ↗

OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.Semantic proximity Read ↗

Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007).Semantic proximity Read ↗

Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study.Semantic proximity Read ↗

Single centre experience with pegylated interferon and ribavirin for hepatitis C: looking back before moving forward.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.